Steatotic Liver Disease: Steatotic Liver Disease: Alcohol and Transplant

0:00Welcome to Board Pearls. This is episode two of two of the Steatotic Liver Disease chapter, in the Liver Disease module. This episode is alcohol-associated liver disease, from its early stages to early transplant. A heavy drinker who asks whether stopping still matters shows how the disease progresses and what reverses at each stage, how alcohol injures the liver, why the aspartate aminotransferase, AST, runs higher than the alanine aminotransferase, ALT, and what an AST over four hundred means. A woman and a Japanese man show why some people are injured at lower doses, and one gene that protects only those who don't drink. A woman with new jaundice and fever shows severe alcohol-associated hepatitis: the diagnosis without a biopsy, the severity scores, what steroids achieve and what has to be excluded first, the day-seven decision, and the supportive care that matters as much as the drug. And a young man who doesn't respond to steroids shows why the six-month rule for transplant fell, who qualifies instead, and how his alcohol use disorder is treated afterward.

1:06Here's the first patient. A fifty-two-year-old man has drunk about eight beers a day for fifteen years. His AST is one hundred thirty, his ALT sixty, and his gamma-glutamyl transpeptidase, GGT, three hundred twenty. His ferritin is high, his mean corpuscular volume, MCV, is one hundred four, and his platelets are one hundred twenty thousand. His liver is enlarged, and his FibroScan shows advanced fibrosis. He asks whether there's any point stopping now, since the damage is done.

1:38He has alcohol-associated liver disease with advanced fibrosis, and the answer to his question depends on where he sits in its course. Alcohol-associated liver disease is a continuum of steatosis, alcoholic steatohepatitis, fibrosis, and cirrhosis, and each stage reverses differently. Drinking above a threshold dose produces steatosis in about ninety percent of heavy drinkers. Ten to thirty-five percent of those progress to steatohepatitis and twenty to forty percent to fibrosis, and ten to twenty percent of all patients with alcohol use disorder eventually develop cirrhosis. The risk climbs steeply above sixty grams a day, some patients go from steatosis straight to cirrhosis without obvious steatohepatitis, and individual susceptibility varies enormously.

2:24His intake puts him clearly in this category. His eight beers, at fourteen grams each, are about one hundred twelve grams a day, close to eight hundred grams a week. That's far above the four hundred twenty grams a week that defines alcohol-associated disease in a man, so he has alcohol-associated liver disease rather than metabolic dysfunction and alcohol-associated liver disease, MetALD.

2:46What reverses answers his question. Steatosis reverses after four to six weeks of abstinence. Steatohepatitis resolves in about half of patients who stop, progresses to cirrhosis in about a third, and stays unchanged in about a fifth, while continued drinking drives most patients to cirrhosis. Once cirrhosis is established, decompensation occurs at about five to ten percent a year and liver cancer at about two to three percent a year, similar to other causes in United States cohorts. He has advanced fibrosis without established cirrhosis, so stopping gives him a real chance of not progressing. Abstinence is the treatment at every stage, and it matters most at his.

3:29The way alcohol injures the liver explains his labs and the drug interactions he now faces. Alcohol dehydrogenase converts ethanol to acetaldehyde, and aldehyde dehydrogenase converts acetaldehyde to acetate, both using NAD. Chronic drinking shifts the ratio of NADH to NAD toward NADH, which inhibits fatty acid beta-oxidation, so steatosis comes first. Acetaldehyde is itself hepatotoxic, forming protein adducts that disrupt cell function and act as antigens for immune-mediated injury.

4:03Chronic drinking also induces CYP2E1, the microsomal ethanol oxidizing system, which makes acetaldehyde too, with reactive oxygen species as a byproduct. That induction explains acetaminophen toxicity at therapeutic doses, isoniazid injury, and faster methotrexate fibrosis in drinkers, and glutathione depletion compounds the oxidative injury. Endotoxins cross the damaged gut barrier and activate Kupffer cells through toll-like receptor four, TLR4, releasing tumor necrosis factor alpha, TNF-alpha, and driving the neutrophil-rich inflammation of alcoholic steatohepatitis. Mallory-Denk bodies, clumps of damaged keratin, and perivenular pericellular fibrosis complete the histology.

4:50His labs show the typical pattern. Outside severe alcoholic hepatitis, the findings are an enlarged liver, an AST greater than the ALT with a ratio over one and a half to two and both usually under four hundred, a high GGT, a high ferritin, mild macrocytosis, and low platelets. The AST runs higher because alcohol is a mitochondrial toxin and AST has a mitochondrial isoform, while the ALT, which is cytoplasmic, needs vitamin B6, and drinkers are depleted of it. His ratio over two, his high GGT and ferritin, and his MCV of one hundred four all fit.

5:31His low platelets change his workup. They could be direct marrow suppression or hypersplenism from portal hypertension. Either way, with platelets under one hundred fifty thousand he doesn't qualify to skip screening endoscopy under the Baveno seven rule, whatever his stiffness.

5:47His AST under four hundred fits too, and a higher one wouldn't. In a drinker, aminotransferases over four hundred point to a superimposed insult, such as acetaminophen toxicity, ischemic hepatitis, or another acute injury, rather than alcohol alone. An AST of eight hundred in this man would call for an acetaminophen level and a medication history, because a drinker with induced CYP2E1 can be injured by an ordinary dose. Alcohol-related cirrhosis can't be told apart from other cirrhosis on histology without the history, so viral hepatitis and the other causes are still excluded. He's counseled on abstinence and referred to addiction medicine, and with advanced liver disease, his drug options for alcohol use disorder are acamprosate or baclofen, covered later in this episode.

6:35The second patient shows that some people are injured at lower doses. A forty-five-year-old woman drinks three glasses of wine a day, about two hundred ninety grams a week, and has the same advanced fibrosis at less than half his intake. Women have lower body water, so their blood alcohol is higher per drink, and they have less gastric alcohol dehydrogenase, so they develop disease at lower thresholds. Her intake is below the three hundred fifty grams a week that defines alcohol-associated disease in a woman, so with a metabolic risk factor she'd be classed as MetALD, but her treatment is the same: stop.

7:11Other risks act the same way. The genetic variants that matter in metabolic dysfunction-associated steatotic liver disease, MASLD, matter here too. PNPLA3 I148M is the dominant risk variant, TM6SF2 E167K adds risk, MBOAT7 is a moderate risk allele particularly in alcohol-associated disease, and loss of function in HSD17B13 protects. Hepatitis C or B plus alcohol drives fibrosis faster than either alone, metabolic risk with moderate drinking carries a worse prognosis than either alone, and coffee protects. Gastric bypass increases alcohol absorption and raises the peak blood alcohol, so every patient after bariatric surgery is asked about drinking, and a modest answer is taken seriously.

7:23The third patient carries a gene that protects at first. A forty-year-old Japanese man flushes, gets a racing heart, and feels nauseated when he drinks, but he keeps drinking. He likely carries ALDH2 star two, a loss-of-function variant common in Asian populations that impairs the clearance of acetaldehyde and causes Asian flush. Historically it reduced drinking, and so reduced alcohol-associated liver disease. But carriers who keep drinking have persistently high acetaldehyde, more adducts, and a markedly raised risk of upper aerodigestive cancers and of liver injury at exposures that wouldn't harm a non-carrier. His flushing is a reason to counsel him firmly against drinking.

7:26Heavy drinking can also produce an acute syndrome on top of the chronic disease, and the fourth patient shows it. A thirty-eight-year-old woman has drunk a bottle of wine or more a day for years. Jaundice began three weeks ago, and she stopped drinking three days ago when she turned yellow. She has a fever of thirty-eight point one, a tender enlarged liver, and mild ascites. Her AST is one hundred eighty, her ALT seventy, her bilirubin sixteen, her international normalized ratio, INR, two point one, and her albumin two point four. Her white count is sixteen thousand, her creatinine one point one, and her Model for End-Stage Liver Disease, MELD, score twenty-six.

7:26New jaundice with fever, a tender liver, and decompensation after years of heavy drinking is severe alcohol-associated hepatitis. It's an acute syndrome on underlying alcohol-associated liver disease: rapid-onset jaundice with ongoing heavy drinking, often with fever, a high white count, an enlarged liver, right upper quadrant pain, and decompensation such as ascites, encephalopathy, and coagulopathy. The AST and ALT are raised but neither goes over four hundred, the ratio is over one and a half and often over two, the bilirubin is over three and often much higher, the INR is raised, and the albumin is low. Mortality at ninety days is thirty to forty percent, so management is aggressive. Her fever and white count can look like infection, and that has to be settled before treatment.

7:26Her diagnosis doesn't need a biopsy. The National Institute on Alcohol Abuse and Alcoholism, NIAAA, consensus criteria define probable alcoholic hepatitis clinically. They require jaundice that began within the prior eight weeks; ongoing heavy use, over forty grams a day in women or sixty in men, for at least six months, with fewer than sixty days of abstinence before the jaundice; an AST of fifty to four hundred, with an AST-to-ALT ratio over one and a half and an ALT under four hundred; and a bilirubin over three. Her jaundice began three weeks ago, her bottle a day is about seventy to eighty grams, and she stopped three days ago. Her AST is one hundred eighty, with a ratio over two and a half and an ALT of seventy, and her bilirubin is sixteen. She has probable alcoholic hepatitis without a biopsy.

7:26A biopsy is needed only when the picture doesn't fit. Definite disease requires a biopsy showing macrovesicular steatosis, ballooning, neutrophilic inflammation, Mallory-Denk bodies, and perivenular pericellular fibrosis. It's needed when abstinence has lasted longer than sixty days, when the labs are atypical, or when another cause is suspected, and it's increasingly done by the transjugular approach because of the coagulopathy. An AST over four hundred breaks the ceiling and calls for another explanation.

7:26Her severity decides whether she's a candidate for steroids. The Maddrey discriminant function is four point six times the prothrombin time minus the control, plus the bilirubin. A value over thirty-two defines severe disease with a markedly raised thirty-day mortality, and it's the threshold above which prednisolone has improved short-term survival since trials in the nineteen seventies. MELD has largely replaced it, because it's more reproducible, it includes creatinine to capture kidney injury, and it predicts longer-term outcome. A MELD over twenty defines severe disease, and the two scores have similar sensitivity, though MELD is more specific. The plain MELD is used here, not MELD-Na. The Glasgow score and the ABIC score, built from age, bilirubin, INR, and creatinine, are alternatives. Her MELD of twenty-six is severe.

7:26Steroids are the only drug with a survival benefit, and a limited one. Prednisolone is forty milligrams by mouth daily for twenty-eight days, or methylprednisolone thirty-two milligrams intravenously when oral drugs aren't possible. In the large modern randomized trial, prednisolone reduced mortality at twenty-eight days, with borderline significance but a clinically meaningful absolute reduction, though not at ninety days or one year, and serious infections were more common on it. The same trial showed no benefit from pentoxifylline, which has been removed from the guidelines.

7:26Her fever means infection has to be excluded first. Steroids are deferred or ruled out by uncontrolled infection, acute kidney injury with a creatinine over two and a half, uncontrolled gastrointestinal, GI, bleeding, active hepatitis B or C, drug-induced liver injury, liver cancer, acute pancreatitis, human immunodeficiency virus, HIV, infection, tuberculosis, and multiorgan failure or shock. She's screened with blood, urine, and ascitic fluid cultures and chest imaging, and many centers observe for twenty-four to seventy-two hours first. In the major trial, the average time from admission to the first dose was six days. Her cultures are negative, her ascitic fluid shows no peritonitis, her chest film is clear, and her creatinine is one point one, so her fever and white count come from the hepatitis, and she starts prednisolone on hospital day three.

7:26A different patient shows when steroids can't be given. A fifty-three-year-old man with severe alcoholic hepatitis has a creatinine of two point nine and spontaneous bacterial peritonitis, and either contraindication alone would defer his steroids. His infection is treated first, he gets the same supportive care, and N-acetylcysteine is a reasonable option. Being ineligible for steroids also makes him a candidate for early transplant evaluation if he doesn't improve.

7:26Her steroids are reassessed on day seven. The Lille score, calculated at day seven from her baseline age, albumin, prothrombin time, bilirubin, and creatinine, plus the change in bilirubin from day zero to day seven, predicts survival at six months far better than Child-Pugh or Maddrey. A score under zero point four five is a response, and the full twenty-eight days continue, with substantially better survival at six months. A score of zero point four five or higher is non-response, and steroids stop, because continuing them adds infection risk without any survival benefit. Some centers use zero point five six to define complete non-response. Non-responders are evaluated for early transplant. Her bilirubin falls from sixteen to nine and her Lille is zero point two, so she completes twenty-eight days.

7:26The care around the steroid matters as much as the drug. In a French randomized trial, intravenous N-acetylcysteine for five days with prednisolone lowered mortality at one month, along with hepatorenal syndrome and infection, though not at six months, and current guidance allows it as a reasonable add-on. Granulocyte colony-stimulating factor, G-CSF, anakinra, interleukin twenty-two, IL-22, and other agents are in trials, not guidelines.

7:26Nutrition is part of the treatment. The target is thirty to forty kilocalories per kilogram a day with one point two to one point five grams of protein per kilogram, by mouth or by nasogastric tube, because intake tracks mortality. An intake under one thousand kilocalories a day predicts near-certain death, and higher intake lowers mortality substantially. Parenteral nutrition is avoided because of its infection risk. Thiamine and other vitamins, withdrawal management, correction of sodium, potassium, magnesium, and phosphorus, and aggressive surveillance for infection are all essential. She's eating little, so she gets a nasogastric tube for her first week, thiamine, electrolyte correction, N-acetylcysteine with her prednisolone, and an addiction medicine consultation before discharge.

7:26The patients whose steroids fail are the ones transplant can save, and the fifth patient shows how they're chosen. A thirty-four-year-old man with severe alcoholic hepatitis and a MELD of thirty-one started prednisolone a week ago. His bilirubin hasn't moved, and his day-seven Lille is zero point seven one. This is his first liver decompensation, and he's never had addiction treatment. His wife and parents are at the bedside every day. He describes his drinking as a disease that nearly killed him, and he and his family commit to lifelong sobriety. He uses no other substances. A resident says transplant is off the table until he's been sober for six months.

7:26He has steroid-unresponsive severe alcoholic hepatitis, and the resident's rule would likely cost him his life. His Lille of zero point seven one means non-response, so his steroids stop today. Steroid-unresponsive severe alcoholic hepatitis carries a mortality of seventy to eighty percent at six months.

7:26The six-month rule fell for good reasons. It was a center policy, not a guideline, it was never validated as a predictor of abstinence after transplant, and it excluded patients with severe alcoholic hepatitis because most died within those six months. It selected survivors, not good candidates. A French study in twenty eleven transplanted twenty-six highly selected non-responders, chosen by a multidisciplinary process for a first decompensating event, commitment from the patient and family to lifelong abstinence, no prior failed addiction treatment, and a supportive social structure without severe psychiatric illness. They were transplanted a median of thirteen days after non-response. Seventy-seven percent survived six months, about three times the rate in matched controls who weren't transplanted, the benefit persisted at two years, and three of the twenty-six returned to any drinking, in line with rates after the six-month rule.

7:26Larger numbers confirmed it. A United States multicenter consortium reported one hundred forty-seven early transplants at twelve centers, with survival of ninety-four percent at one year and eighty-four percent at three, comparable to other indications. Sustained drinking after transplant occurred in about seventeen to twenty-two percent, predicted most by younger age, prior legal or social consequences of alcohol, and inadequate insight. That told the field what to assess rather than how long to wait.

7:26His candidacy is judged by addiction medicine and a multidisciplinary transplant team, using structured tools. The Stanford Integrated Psychosocial Assessment for Transplantation, SIPAT, scores readiness and adherence, the social support system, psychosocial stability and psychopathology, and the effects of lifestyle and substance use. Higher scores mean higher risk, running from an excellent candidate at zero to six, through good, minimally acceptable, and poor, to high risk and not recommended at seventy or higher. The High Risk Alcoholism Relapse score adds the duration of heavy drinking, the number of daily drinks, and prior treatment. A selection committee weighs these with the addiction medicine assessment and the wider picture, so the job at the bedside is to recognize the candidate, stop the steroids, and get him to that team quickly.

7:26The selection criteria are set out in the twenty nineteen American Association for the Study of Liver Diseases, AASLD, practice guidance and the twenty twenty-four American College of Gastroenterology, ACG, guideline. They are a first liver-decompensating event; failure of or ineligibility for medical therapy, meaning a Lille of zero point four five or higher or a contraindication to steroids; no severe medical comorbidities; a supportive network of at least two close family members or supports; no more than one prior failed alcohol treatment attempt; no other active substance use disorder and no untreated severe psychiatric disease; insight into alcohol use disorder; and an explicit commitment to lifelong sobriety from the patient and family.

7:26He meets all eight, so he's referred for early transplant evaluation now. Continuing steroids, adding N-acetylcysteine, more nutrition, or palliative care alone won't change a mortality of seventy to eighty percent. His SIPAT places him as a good candidate, the committee approves him, and he's transplanted nine days later.

7:26The same criteria can say no. A forty-six-year-old woman with a day-seven Lille of zero point six has had two prior alcohol-related decompensations and three treatment programs, uses methamphetamine, and lives alone, estranged from her family. She meets only the non-response criterion, and her unfavorable features are the predictors of relapse, so she isn't a candidate for early transplant now. Her steroids stop, and she gets supportive care, addiction treatment, and a frank conversation about her prognosis. The criteria judge who's likely to keep a transplanted liver, not a patient's worth.

7:26His care after transplant has three parts: treating his alcohol use disorder, watching for relapse, and standard immunosuppression. Acamprosate and baclofen are the recommended drugs for alcohol use disorder in significant liver disease. Acamprosate doesn't undergo hepatic metabolism, and baclofen, ten milligrams three times a day, improved abstinence in alcohol-related cirrhosis. Disulfiram and oral naltrexone are metabolized by the liver and are used cautiously, and multidisciplinary addiction support is essential.

7:26Long-term outcomes match other indications, with cardiovascular disease and new cancers emerging as major causes of death outside the liver. Alcohol-associated liver disease has been the leading transplant indication in the United States since twenty sixteen, passing hepatitis C as direct-acting antivirals spread. He starts acamprosate and counseling, and at two years he remains abstinent, with normal graft function. Chapter twenty-four covers transplant in general.

7:26Here are the traps the boards set in these patients. Steatohepatitis isn't permanent damage, and established cirrhosis doesn't reverse. An AST of eight hundred in a drinker isn't alcohol alone. A low ALT from B6 deficiency is what drives the ratio. Women, PNPLA3 carriers, people with viral hepatitis, and patients after gastric bypass are injured at lower doses. ALDH2 star two carriers who keep drinking face a higher cancer risk. And cirrhosis isn't called alcoholic without excluding the other causes.

7:26The alcoholic hepatitis traps follow. A biopsy isn't needed when the NIAAA criteria are met. An AST over four hundred isn't alcoholic hepatitis. Severity uses MELD, not MELD-Na, and mild disease doesn't get steroids. Steroids don't start before infection is screened for, and they aren't given with a creatinine over two and a half or an active infection. Pentoxifylline doesn't help. Steroids stop at a day-seven Lille of zero point four five or higher. And underfeeding and parenteral nutrition both cost lives.

7:26The transplant traps close the list. Six months of sobriety isn't required before referral. Referral isn't delayed for more nutrition or N-acetylcysteine. Being ineligible for steroids meets the medical-therapy criterion. Prior decompensations, multiple failed treatments, and other active substance use weigh against candidacy. Structured psychosocial assessment isn't skipped. And disulfiram and naltrexone aren't used freely after transplant.

7:26So, start to finish. Alcohol-associated liver disease runs from reversible steatosis through steatohepatitis to cirrhosis, and abstinence is the treatment at every stage. Acetaldehyde, a shifted NADH ratio, CYP2E1 induction, and gut endotoxin drive the injury. The AST runs about twice the ALT, both under four hundred, with a high GGT and macrocytosis, and an AST over four hundred means another insult. Women, PNPLA3 carriers, and people with obesity, viral hepatitis, or prior bypass are injured at lower doses, and ALDH2 star two carriers who drink face aerodigestive cancer.

7:26Diagnose alcoholic hepatitis by the NIAAA criteria, and biopsy only when the picture doesn't fit. Severe disease is a MELD over twenty or a Maddrey over thirty-two. Screen for infection, then give prednisolone forty milligrams daily unless a contraindication forbids it, with N-acetylcysteine as a reasonable add-on, enteral nutrition, thiamine, and electrolyte care. At day seven, a Lille under zero point four five means finishing twenty-eight days, and zero point four five or higher means stopping.

7:26Refer a steroid non-responder, or a patient ineligible for steroids, for early transplant when there's a first decompensation, no severe comorbidity, at least two close supports, no more than one failed treatment, no other active substance use or untreated severe psychiatric illness, insight, and a commitment to lifelong sobriety, judged by structured assessment such as SIPAT, without a six-month rule. After transplant, treat alcohol use disorder with acamprosate or baclofen.

7:26That completes the Steatotic Liver Disease chapter. The next chapter is inherited liver diseases.

7:26For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode two of two of chapter twenty-one, and I'll see you in the next one.